In the realm of natural compounds with significant medicinal potential, Tanshinone IIA stands out as a subject of intense research and interest. But what exactly is the mechanism of action of it? This powerful compound holds the promise of numerous therapeutic benefits, yet its mode of operation remains a mystery waiting to be unraveled. In this blog, we will embark on a journey to explore the intricate mechanisms through which it exerts its effects.
What is it and its significance in medicine?
Tanshinone IIA is a major component extracted from the roots of Salvia miltiorrhiza Bunge. It holds significant importance in medicine due to its diverse pharmacological activities. This compound has shown potential in treating various diseases, including tumors, cardiac hypertrophy, and ischemic stroke.
Anti-tumor Effects
-- Anti-tumor Mechanisms
1. Regulation of cell cycle.
It has been found to regulate the cell cycle of tumor cells. By interfering with specific stages of the cell cycle, it can prevent the uncontrolled growth of cancer cells. For example, studies have shown that it can arrest cells in certain phases, thereby inhibiting their proliferation.
2. Inhibition of cell proliferation.
The compound can directly inhibit the proliferation of tumor cells. In experiments on various cancer cell lines such as A549 cells (human non-small cell lung cancer cells), it has been demonstrated that Tanshinone IIA can significantly suppress cell growth in a dose and time-dependent manner. The IC50 values for A549 cells after 24, 48, and 72 hours are 145.3, 30.95, and 11.49 μM respectively. CCK-8 assays have confirmed that it can reduce the proliferative activity of these cells.
3. Induction of cell apoptosis.
It can also induce apoptosis in tumor cells. Apoptosis is a programmed cell death process that can help eliminate cancer cells. In A549 cells, for instance, exposure to Tanshinone IIA (31 μM) for 48 hours leads to obvious apoptosis and cell growth inhibition. Western blotting has revealed that the expression of VEGF and VEGFR2 protein is downregulated in drug-treated groups compared to the control group.
4. Inhibition of tumor invasion and metastasis.
In addition to affecting cell proliferation and apoptosis, Tanshinone IIA can inhibit the invasion and metastasis of tumor cells. By targeting specific molecules and pathways involved in these processes, it can prevent cancer cells from spreading to other parts of the body. For example, it has been shown to reduce the protein expression of EGFR and IGFR, which are involved in the PI3K/Akt/mTOR pathway that is associated with tumor invasion and metastasis.
5. Suppression of angiogenesis.
It may inhibit angiogenesis by targeting VEGF/VEGFR2. It is believed that this compound can target the protein kinase domain of VEGF/VEGFR2, thereby suppressing the formation of new blood vessels and cutting off the supply of nutrients and oxygen to tumors.
6. Reversal of tumor multidrug resistance.
It has the potential to reverse tumor multidrug resistance. This is an important aspect as it can enhance the effectiveness of chemotherapy drugs. By modulating specific mechanisms involved in drug resistance, it can make cancer cells more susceptible to treatment.
Effects on Cardiac Hypertrophy
-- Mechanisms in Attenuating Cardiac Hypertrophy
1. Regulation through miR-133 and calcineurin pathway.
Studies have shown that Tanshinone IIA can effectively reverse rat myocardial hypertrophy induced by transverse aortic constriction (TAC). The mechanism is related to its regulation of miR-133 and the calcineurin pathway. In experiments, 60 SD rats were randomly divided into three groups: sham operation group, surgery group, and Tanshinone treatment group. The results showed that Tanshinone treatment significantly improved myocardial hypertrophy. The levels of regulatory calcineurin interacting protein 1 (MCIP1) and miR-133 in the surgery group were significantly different from those in the other two groups. The MCIP1 level in the Tanshinone group was significantly higher than that in the sham operation group, while the miR-133 level was lower than that in the sham operation group. The protein level of calcineurin in the surgery group was significantly higher than that in the other two groups, and there was no significant difference between the Tanshinone group and the sham operation group. The 32P release in the surgery group was higher than that in the other two groups, and the 32P release in the Tanshinone group was higher than that in the sham operation group. These results suggest that Tanshinone IIA can regulate miR-133 to reduce calcineurin and thereby improve myocardial hypertrophy.
Treatment of Ischemic Stroke
-- Mechanisms in Ischemic Stroke Treatment
1. Identification of targets and pathways.
Researchers have used network pharmacology to explore the mechanism of Tanshinone IIA in treating ischemic stroke. Through databases such as PubChem, PharmMapper, UniProt, and GeneCards, they have identified 70 targets related to Tanshinone and 3,350 gene targets related to ischemic stroke. Among them, there are 16 key targets for Tanshinone in treating ischemic stroke.
2. GO and KEGG enrichment analysis.
GO and KEGG enrichment analysis of these 16 targets revealed that Tanshinone treatment of ischemic stroke involves 87 GO entries. These include biological functions such as nuclear receptor activity, ligand-activated transcription factor activity, steroid hormone receptor activity, MAP kinase activity, scaffold protein binding, protein serine/threonine kinase activity, ATPase binding, β-catenin binding, steroid binding, and MAP kinase kinase activity. It mainly involves nine KEGG signal pathways, including endocrine resistance, FoxO signaling pathway, EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, ErbB signaling pathway, Rap1 signaling pathway, Ras signaling pathway, HIF-1 signaling pathway, and platinum resistance.
Molecular docking results.
Molecular docking results showed that Tanshinone IIA has strong binding activity with five key proteins such as PGＲ, CDK2, MAPK1, KDＲ, and EGFＲ.
In conclusion, Tanshinone IIA exhibits diverse mechanisms of action. In the field of anti-tumor, it can regulate the cell cycle, inhibit cell proliferation, induce apoptosis, inhibit invasion and metastasis, suppress angiogenesis, and reverse multidrug resistance. In the treatment of cardiac hypertrophy, it can regulate through the miR-133 and calcineurin pathway. In the treatment of ischemic stroke, it acts through multiple targets and pathways. These findings suggest that Tanshinone has great potential in the field of medicine and warrants further research and exploration.
JOYWIN founded in 2013 is an innovation-driven biotechnology company. We provide the manufacture of plant extracts, plant proteases, and customized products. If you want to know more about Tanshinone IIA or are interested in purchasing it, you can send an email to contact@joywinworld.com. We will reply to you as soon as possible after we see the message.